G1 Therapeutics, Inc.
Symbol: GTHX
NASDAQ
4.44
USDMarktpreis heute
-7.4160
P/E-Verhältnis
-0.3307
PEG-Verhältnis
232.23M
MRK Kapital
- 0.00%
DIV Rendite
G1 Therapeutics, Inc. (GTHX) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 345.99 | 82.2 | 145.1 | 221.2 | ||||||||||
balance-sheet.row.short-term-investments | 185.28 | 49.9 | 50.5 | 0 | ||||||||||
balance-sheet.row.net-receivables | 46.78 | 12.7 | 11.1 | 5.7 | ||||||||||
balance-sheet.row.inventory | 54.08 | 12.4 | 16.2 | 3.5 | ||||||||||
balance-sheet.row.other-current-assets | 30.42 | 7.6 | 7.1 | 13.2 | ||||||||||
balance-sheet.row.total-current-assets | 477.33 | 114.9 | 179.5 | 243.6 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 26.32 | 6.4 | 8 | 9 | ||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-investments | 0.62 | 0.2 | 0.3 | 0.3 | ||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-non-current-assets | 0.28 | 0 | 0.3 | 1.2 | ||||||||||
balance-sheet.row.total-non-current-assets | 27.23 | 6.6 | 8.5 | 10.5 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 504.55 | 121.5 | 188 | 254.1 | ||||||||||
balance-sheet.row.account-payables | 22.2 | 4 | 7.4 | 2.9 | ||||||||||
balance-sheet.row.short-term-debt | 31.9 | 1.3 | 1.1 | 1.1 | ||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-debt-total | 116.16 | 51.6 | 82.6 | 81.9 | ||||||||||
Deferred Revenue Non Current | 2 | 0.5 | 1 | 1 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -46.6 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 73.94 | 23.8 | 27 | 23.6 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 210.97 | 56.4 | 83.6 | 82.9 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 18.01 | 4.3 | 6.8 | 7.9 | ||||||||||
balance-sheet.row.total-liab | 340.86 | 86.2 | 119.2 | 110.6 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0.02 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.retained-earnings | -3090.2 | -780 | -732 | -584.5 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 2441.74 | 815.4 | 800.8 | 0 | ||||||||||
balance-sheet.row.total-stockholders-equity | -648.43 | 35.4 | 68.7 | -584.5 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | -307.57 | 121.5 | 188 | -473.9 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | -648.43 | 35.4 | 68.7 | -584.5 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | -307.57 | - | - | - | ||||||||||
Total Investments | 185.47 | 50.1 | 50.5 | 0.3 | ||||||||||
balance-sheet.row.total-debt | 127.72 | 57.2 | 83.8 | 83.1 | ||||||||||
balance-sheet.row.net-debt | -74.71 | 24.9 | -10.8 | -138.1 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -30.59 | -48 | -147.6 | -148.4 | ||||||||||
cash-flows.row.depreciation-and-amortization | 0.5 | 0.5 | 0.5 | 0.5 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | 1.2 | 0 | 0.6 | ||||||||||
cash-flows.row.stock-based-compensation | 10.67 | 14.5 | 20.6 | 22.3 | ||||||||||
cash-flows.row.change-in-working-capital | 1.14 | -5.2 | -5.3 | -8.8 | ||||||||||
cash-flows.row.account-receivables | 4.37 | -1.6 | -5.4 | -5.5 | ||||||||||
cash-flows.row.inventory | 3 | 3.7 | -12.7 | -3.5 | ||||||||||
cash-flows.row.account-payables | -0.37 | -3.4 | 4.4 | -0.7 | ||||||||||
cash-flows.row.other-working-capital | -4.26 | -4 | 8.4 | 0.8 | ||||||||||
cash-flows.row.other-non-cash-items | 9.12 | -1.4 | 3.1 | 1.7 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -18.18 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 50 | 0 | ||||||||||
cash-flows.row.purchases-of-investments | -116.81 | -124.7 | -65 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 122 | 127.5 | 15 | 0 | ||||||||||
cash-flows.row.other-investing-activites | -0.1 | 0 | -50 | 0 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 5.19 | 2.8 | -50.5 | 0 | ||||||||||
cash-flows.row.debt-repayment | -26.69 | -26.7 | 0 | -53.6 | ||||||||||
cash-flows.row.common-stock-issued | -0.01 | -0.2 | 52.4 | 86.4 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-financing-activites | -8.76 | -0.3 | 0.1 | 113.1 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -35.42 | -26.9 | 52.5 | 145.9 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0.1 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -48.41 | -62.4 | -126.7 | 13.8 | ||||||||||
cash-flows.row.cash-at-end-of-period | 161.52 | 32.3 | 94.9 | 221.6 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 209.93 | 94.7 | 221.6 | 207.8 | ||||||||||
cash-flows.row.operating-cash-flow | -18.18 | -38.3 | -128.6 | -132.1 | ||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.free-cash-flow | -18.18 | -38.3 | -129.1 | -132.1 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 84.04 | 82.5 | 51.3 | 31.5 | ||||||||||
income-statement-row.row.cost-of-revenue | 6.82 | 7.2 | 3.7 | 2 | ||||||||||
income-statement-row.row.gross-profit | 77.23 | 75.3 | 47.6 | 29.5 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 35.55 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 5.27 | 2.2 | 0 | -0.3 | ||||||||||
income-statement-row.row.operating-expenses | 102.6 | 114.8 | 183.7 | 171.9 | ||||||||||
income-statement-row.row.cost-and-expenses | 106.34 | 122 | 187.5 | 173.9 | ||||||||||
income-statement-row.row.interest-income | 2.04 | 2.5 | 0.7 | 0 | ||||||||||
income-statement-row.row.interest-expense | 0.74 | 10 | 10.4 | 4.7 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | -2.58 | -5.3 | -9.7 | -5 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 5.27 | 2.2 | 0 | -0.3 | ||||||||||
income-statement-row.row.total-operating-expenses | -2.58 | -5.3 | -9.7 | -5 | ||||||||||
income-statement-row.row.interest-expense | 0.74 | 10 | 10.4 | 4.7 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 0.51 | 0.5 | 1.3 | -0.3 | ||||||||||
income-statement-row.row.ebitda-caps | -21.23 | - | - | - | ||||||||||
income-statement-row.row.operating-income | -22.83 | -39.5 | -136.2 | -142.5 | ||||||||||
income-statement-row.row.income-before-tax | -27.48 | -44.9 | -145.9 | -147.4 | ||||||||||
income-statement-row.row.income-tax-expense | 3.12 | 3.1 | 1.7 | 0.9 | ||||||||||
income-statement-row.row.net-income | -30.59 | -48 | -147.6 | -148.4 |
Häufig gestellte Frage
Wie hoch ist die G1 Therapeutics, Inc. (GTHX) Gesamtvermögen?
G1 Therapeutics, Inc. (GTHX) Gesamtvermögen ist 121540000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 29349000.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.919.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist -0.356.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist -0.364.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist -0.272.
Was ist der G1 Therapeutics, Inc. (GTHX) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist -47967000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 57173000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 114843000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 19887000.000.